Table 1 Baseline characteristics of participants included in the cross-sectional analysis across categories of NT-proBNP.

From: Longitudinal and cross-sectional associations of myocardial stress markers with kidney function and chronic kidney disease in the BiomarCaRE project

Characteristics

Categories of NT-proBNPa

P-valueb

Total

(N = 61,830)

G1

(N = 30,939)

G2

(N = 21,284)

G3

(N = 7109)

G4

(N = 2498)

Mean (standard deviation) or number (%)

Study cohort, N (%)

     

 < 0.001

FINRISK

6858 (11.1)

3468 (11.2)

2359 (11.1)

775 (10.9)

256 (10.2)

 

MONICA/KORA

5790 (9.4)

2834 (9.2)

2081 (9.8)

661 (9.3)

214 (8.6)

 

Moli-sani

22,243 (36.0)

10,672 (34.5)

7764 (36.5)

2753 (38.7)

1054 (42.2)

 

MONICA_Brianza

3623 (5.9)

2136 (6.9)

1143 (5.4)

281 (4.0)

63 (2.5)

 

Northern Sweden MONICA

10,414 (16.8)

5560 (18.0)

3435 (16.1)

1026 (14.4)

393 (15.7)

 

PRIME/Belfast

1539 (2.5)

1010 (3.3)

403 (1.9)

82 (1.2)

44 (1.8)

 

SHHEC

11,363 (18.4)

5259 (17.0)

4099 (19.3)

1531 (21.5)

474 (19.0)

 

Age (years)

51.8 (12.5)

47.7 (10.9)

53.1 (12.0)

60.2 (12.1)

66.3 (10.7)

 < 0.001

Sex, N (%) female

32,209 (52.1)

12,716 (41.1)

13,755 (64.6)

4574 (64.3)

1164 (46.6)

 < 0.001

Body mass index (kg/m2)

27.2 (6.07)

27.1 (5.74)

27.0 (6.24)

27.7 (6.29)

28.6 (7.46)

 < 0.001

Current smoker, N (%)

17,229 (27.9)

9424 (30.5)

5631 (26.5)

1637 (23.0)

537 (21.5)

 < 0.001

Alcohol consumption, N (%)

     

 < 0.001

No alcohol consumption

20,265 (32.8)

9160 (29.6)

7546 (35.5)

2670 (37.6)

889 (35.6)

 

 > 0 and < 20 g/day

27,001 (43.7)

13,646 (44.1)

9324 (43.8)

3014 (42.4)

1017 (40.7)

 

 ≥ 20 g/day

14,564 (23.6)

8133 (26.3)

4414 (20.7)

1425 (20.0)

592 (23.7)

 

Systolic blood pressure (mm Hg)

135.8 (32.5)

132.3 (32.5)

136.0 (32.0)

144.3 (28.0)

152.1 (39.1)

 < 0.001

Use of antihypertensive medication, N (%)

11,096 (17.9)

3420 (11.1)

4076 (19.2)

2354 (33.1)

1246 (49.9)

 < 0.001

Hypertension, N (%)

27,574 (44.6)

11,352 (36.7)

9804 (46.1)

4485 (63.1)

1933 (77.4)

 < 0.001

HDL-cholesterol (mmol/L)

1.46 (0.39)

1.41 (0.37)

1.51 (0.40)

1.51 (0.42)

1.41 (0.41)

 < 0.001

LDL-cholesterol (mmol/L)

3.37 (1.02)

3.39 (1.00)

3.37 (1.02)

3.35 (1.05)

3.31 (1.09)

 < 0.001

Triglycerides (mmol/L), median [IQR]

1.26 [0.91, 1.78]

1.28 [0.91, 1.83]

1.21 [0.89, 1.70]

1.29 [0.95, 1.80]

1.38 [1.03, 1.87]

 < 0.001

Diabetes, N (%)

2890 (4.7)

1040 (3.4)

955 (4.5)

538 (7.6)

357 (14.3)

 < 0.001

Cardiovascular diseases, N (%)

2563 (4.1)

528 (1.7)

730 (3.4)

708 (10.0)

597 (23.9)

 < 0.001

eGFRcr (ml/min/1.73 m2)

97.3 (16.7)

100.8 (15.6)

96.4 (15.7)

90.3 (16.8)

80.7 (20.4)

 < 0.001

CKDcr, N (%)

1833 (3.0)

539 (1.7)

543 (2.6)

364 (5.1)

387 (15.5)

 < 0.001

eGFRcys (ml/min/1.73 m2)

94.4 (22.5)

99.5 (20.1)

93.3 (21.6)

84.0 (24.4)

71.3 (26.4)

 < 0.001

CKDcys, N (%)

4663 (7.5)

878 (2.8)

1562 (7.3)

1310 (18.4)

913 (36.5)

 < 0.001

eGFRcr-cys (ml/min/1.73 m2)

99.1 (19.4)

103.5 (17.4)

98.2 (18.4)

90.2 (20.6)

78.2 (23.6)

 < 0.001

CKDcr-cys, N (%)

1956 (3.2)

365 (1.2)

530 (2.5)

538 (7.6)

523 (20.9)

 < 0.001

MR-proADM, (nmol/l), median [IQR]c

0.47 [0.39, 0.56]

0.44 [0.37, 0.51]

0.48 [0.41, 0.58]

0.55 [0.47, 0.66]

0.65 [0.56, 0.78]

 < 0.001

MR-proANP, (pmol/l), median [IQR]c

48.1 [35.2, 67.6]

39.6 [30.5, 52.6]

53.9 [41.7, 70.8]

78.9 [59.3, 103.0]

127.5 [91.4, 183.5]

 < 0.001

NT-proBNP, (pg/ml), median [IQR]

48.0 [25.4, 89.6]

25.4 [15.9, 35.6]

72.5 [58.9, 92.1]

169.4 [142.6, 209.3]

501.2 [367.7, 837.2]

 < 0.001

  1. aCategories of NT-proBNP: G1: < 48; G2: 48–125; G3: 125–300; G4: ≥ 300 pg/ml.
  2. bP-value was estimated by ANOVA test/Kruskal–Wallis test (continuous variables), or chi-squared test (categorical variables).
  3. cMR-proADM and MR-proANP are only available in the FINRISK and PRIME/Belfast studies.
  4. CKD, chronic kidney disease; cr, creatinine-based; cys, cystatin C-based; cr-cys, combined creatinine and cystatin C-based; eGFR, estimated glomerular filtration rate; G, group; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Back to article page